DENTSPLY SIRONA (NASDAQ:XRAY) Releases FY 2022 Earnings Guidance

DENTSPLY SIRONA (NASDAQ:XRAYGet Rating) updated its FY 2022 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $2.35-$2.55 for the period, compared to the consensus estimate of $2.77. The company issued revenue guidance of $4.10 billion-$4.20 billion, compared to the consensus revenue estimate of $4.23 billion.

Several research firms recently weighed in on XRAY. HC Wainwright cut their target price on shares of DENTSPLY SIRONA from $58.00 to $48.00 and set a hold rating for the company in a research note on Friday, April 22nd. Robert W. Baird lowered shares of DENTSPLY SIRONA from an outperform rating to a neutral rating and lowered their target price for the stock from $67.00 to $48.00 in a report on Tuesday, April 19th. William Blair lowered shares of DENTSPLY SIRONA from an outperform rating to a market perform rating in a report on Tuesday, April 19th. Bank of America lowered shares of DENTSPLY SIRONA from a buy rating to a neutral rating and decreased their price objective for the company from $66.00 to $49.00 in a report on Tuesday, April 19th. Finally, TheStreet lowered shares of DENTSPLY SIRONA from a b- rating to a c+ rating in a report on Friday, March 18th. Six investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of Hold and an average price target of $52.89.

Shares of XRAY traded up $0.72 during mid-day trading on Wednesday, reaching $38.82. 5,434 shares of the company’s stock were exchanged, compared to its average volume of 2,292,417. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.45 and a quick ratio of 1.03. The stock has a market capitalization of $8.36 billion, a PE ratio of 22.54 and a beta of 0.94. The business’s fifty day simple moving average is $44.12 and its 200-day simple moving average is $50.23. DENTSPLY SIRONA has a 52-week low of $35.00 and a 52-week high of $68.02.

DENTSPLY SIRONA (NASDAQ:XRAYGet Rating) last released its earnings results on Tuesday, May 10th. The medical instruments supplier reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.50 by $0.02. DENTSPLY SIRONA had a return on equity of 11.63% and a net margin of 8.81%. The company had revenue of $9.67 billion during the quarter, compared to the consensus estimate of $982.05 million. During the same quarter last year, the company earned $0.72 earnings per share. DENTSPLY SIRONA’s quarterly revenue was up 841.1% compared to the same quarter last year. Equities research analysts predict that DENTSPLY SIRONA will post 2.41 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, April 8th. Investors of record on Friday, March 25th were given a dividend of $0.125 per share. This represents a $0.50 dividend on an annualized basis and a yield of 1.29%. The ex-dividend date was Thursday, March 24th. This is a boost from DENTSPLY SIRONA’s previous quarterly dividend of $0.11. DENTSPLY SIRONA’s dividend payout ratio (DPR) is currently 29.59%.

In related news, Director Eric Brandt sold 6,900 shares of DENTSPLY SIRONA stock in a transaction dated Tuesday, May 3rd. The stock was sold at an average price of $39.71, for a total transaction of $273,999.00. Following the completion of the sale, the director now owns 35,155 shares in the company, valued at approximately $1,396,005.05. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.76% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the business. Allstate Corp lifted its position in DENTSPLY SIRONA by 6.1% during the 4th quarter. Allstate Corp now owns 5,671 shares of the medical instruments supplier’s stock worth $316,000 after acquiring an additional 324 shares in the last quarter. Captrust Financial Advisors raised its position in shares of DENTSPLY SIRONA by 14.0% in the 1st quarter. Captrust Financial Advisors now owns 4,446 shares of the medical instruments supplier’s stock valued at $219,000 after purchasing an additional 546 shares in the last quarter. Parkside Financial Bank & Trust raised its position in shares of DENTSPLY SIRONA by 163.7% in the 1st quarter. Parkside Financial Bank & Trust now owns 915 shares of the medical instruments supplier’s stock valued at $46,000 after purchasing an additional 568 shares in the last quarter. MML Investors Services LLC raised its position in shares of DENTSPLY SIRONA by 4.5% in the 4th quarter. MML Investors Services LLC now owns 14,236 shares of the medical instruments supplier’s stock valued at $794,000 after purchasing an additional 618 shares in the last quarter. Finally, SkyView Investment Advisors LLC raised its position in shares of DENTSPLY SIRONA by 17.0% in the 1st quarter. SkyView Investment Advisors LLC now owns 4,878 shares of the medical instruments supplier’s stock valued at $240,000 after purchasing an additional 710 shares in the last quarter. Institutional investors own 94.79% of the company’s stock.

About DENTSPLY SIRONA (Get Rating)

DENTSPLY SIRONA Inc designs, develops, manufactures, distributes, and sells various dental products and technologies for professional dental market worldwide. It offers dental equipment, including treatment centers, imaging equipment, motorized dental handpieces, and other instruments; imaging equipment; treatment centers comprising basic dentist chairs, sophisticated chair-based units with integrated diagnostic, hygiene and ergonomic functionalities, and specialist centers; and lab equipment, such as amalgamators, mixing machines, and porcelain furnaces.

See Also

Earnings History and Estimates for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.